147 related articles for article (PubMed ID: 8887014)
1. Therapeutic effect of benfluorex in type II diabetic patients on diet regimen alone.
Velussi M; Monte AD; Cernigoi AM
J Diabetes Complications; 1996; 10(5):261-6. PubMed ID: 8887014
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic benefit of benfluorex in type II diabetic patients treated with sulfonylureas.
Stucci N; de Gregoris P; Lavielle R; Tomasi F
J Diabetes Complications; 1996; 10(5):267-73. PubMed ID: 8887015
[TBL] [Abstract][Full Text] [Related]
3. Addition of benfluorex to biguanide improves glycemic control in obese non-insulin-dependent diabetes: a double-blind study versus placebo.
Roger P; Auclair J; Drain P
J Diabetes Complications; 1999; 13(2):62-7. PubMed ID: 10432168
[TBL] [Abstract][Full Text] [Related]
4. Added benfluorex in obese insulin-requiring type 2 diabetes.
Leutenegger M; Bauduceau B; Brun JM; Guillon-Metz F; Martin C; Nicolino-Peltier C; Richard JL; Vannereau D
Diabetes Metab; 1998 Feb; 24(1):55-61. PubMed ID: 9534010
[TBL] [Abstract][Full Text] [Related]
5. Benfluorex decreases insulin resistance and improves lipid profiles in obese type 2 diabetic patients.
Bianchi R; Bongers V; Bravenboer B; Erkelens DW
Diabetes Metab Rev; 1993 Nov; 9 Suppl 1():29S-34S. PubMed ID: 8299486
[TBL] [Abstract][Full Text] [Related]
6. Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients.
Del Prato S; Erkelens DW; Leutenegger M
Acta Diabetol; 2003 Mar; 40(1):20-7. PubMed ID: 12682825
[TBL] [Abstract][Full Text] [Related]
7. Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
Pontiroli AE; Pacchioni M; Piatti PM; Cassisa C; Camisasca R; Pozza G
J Clin Endocrinol Metab; 1996 Oct; 81(10):3727-32. PubMed ID: 8855830
[TBL] [Abstract][Full Text] [Related]
8. [Mechanisms of hypoglycemic action of benfluorex].
Vigili de Kreutzenberg S; Riccio A; Dorella M; Da Tos V; Del Prato S
Presse Med; 1992 Sep; 21(28):1340-3. PubMed ID: 1438104
[TBL] [Abstract][Full Text] [Related]
9. Benfluorex and blood glucose control in non insulin-dependent diabetic patients.
Cavallo-Perin P; Estivi P; Boine L; Galletti R; Pacini G; Cobelli C; Pagano G
J Endocrinol Invest; 1991 Feb; 14(2):109-13. PubMed ID: 2061566
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: an 18-week, randomized, double-blind study.
Moulin P; Andre M; Alawi H; dos Santos LC; Khalid AK; Koev D; Moore R; Serban V; Picandet B; Francillard M
Diabetes Care; 2006 Mar; 29(3):515-20. PubMed ID: 16505498
[TBL] [Abstract][Full Text] [Related]
11. Effects of insulin reduction with benfluorex on serum dehydroepiandrosterone (DHEA), DHEA sulfate, and blood pressure in hypertensive middle-aged and elderly men.
Nestler JE; Beer NA; Jakubowicz DJ; Colombo C; Beer RM
J Clin Endocrinol Metab; 1995 Feb; 80(2):700-6. PubMed ID: 7852539
[TBL] [Abstract][Full Text] [Related]
12. Mechanism(s) of the blood glucose lowering action of benfluorex.
Riccio A; Vigili de Kreutzenberg S; Dorella M; Da Tos V; De Biasi L; Marescotti MC; Tiengo A; Del Prato S
Diabetes Metab Rev; 1993 Nov; 9 Suppl 1():19S-27S. PubMed ID: 8299485
[TBL] [Abstract][Full Text] [Related]
13. Benfluorex normalizes hyperglycemia and reverses hepatic insulin resistance in STZ-induced diabetic rats.
Serradas P; Blondel O; Bailbe D; Portha B
Diabetes; 1993 Apr; 42(4):564-70. PubMed ID: 8454107
[TBL] [Abstract][Full Text] [Related]
14. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
15. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
Halpern A; Mancini MC; Suplicy H; Zanella MT; Repetto G; Gross J; Jadzinsky M; Barranco J; Aschner P; Ramirez L; Matos AG
Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: an 18 to 34-week, open-label, extension period.
Moulin P; André M; Alawi H; Dos Santos LC; Khalid AK; Koev D; Moore R; Serban V; Picandet B; Francillard M
Diabetes Metab; 2009 Feb; 35(1):64-70. PubMed ID: 19150252
[TBL] [Abstract][Full Text] [Related]
17. Increased glycemic variability and decrease of the postprandial glucose contribution to HbA1c in obese subjects across the glycemic continuum from normal glycemia to first time diagnosed diabetes.
Fysekidis M; Cosson E; Banu I; Duteil R; Cyrille C; Valensi P
Metabolism; 2014 Dec; 63(12):1553-61. PubMed ID: 25308444
[TBL] [Abstract][Full Text] [Related]
18. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
[TBL] [Abstract][Full Text] [Related]
19. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group.
Chan JC; Chan KW; Ho LL; Fuh MM; Horn LC; Sheaves R; Panelo AA; Kim DK; Embong M
Diabetes Care; 1998 Jul; 21(7):1058-61. PubMed ID: 9653595
[TBL] [Abstract][Full Text] [Related]
20. Effect of benfluorex on insulin secretion and insulin action in streptozotocin-diabetic rats.
Portha B; Serradas P; Bailbé D; Blondel O; Picarel F
Diabetes Metab Rev; 1993 Nov; 9 Suppl 1():57S-63S. PubMed ID: 8299491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
